Cerus Corporation
1.4500-0.05 (-3.33%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · CERS · USD
Key Stats
Market Cap
277.96MP/E (TTM)
-Basic EPS (TTM)
-0.10Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Cerus Corporation's Q2 FY2025 results showed product revenue climbing 16% y/y to $52.4M, driven by stronger disposable platelet kit sales in Europe, while government contract revenue jumped 41% y/y to $7.7M on BARDA funding. Gross margin held steady at 55% for the quarter, but improved to 57% for the half-year, reflecting better inventory management amid higher U.S. kit volumes. Operating loss narrowed to $3.4M from $3.8M y/y, yet net loss edged wider to $5.7M due to foreign exchange hits and interest costs; diluted EPS stayed at $(0.03), aligning with 191M shares. Cash and equivalents dipped to $16.0M with $62.0M in short-term investments, while total debt held at $85.0M under term and revolving facilities maturing 2028. Free cash flow turned negative at $(3.9M) for the half-year (derived), reflecting inventory builds. No M&A or major regulatory shifts noted. Regulatory hurdles persist, potentially delaying red blood cell system approvals.
8-K
Q2 revenue surges 19%
Cerus Corporation reported Q2 2025 total revenue of $60.1 million, up 19% year-over-year, driven by record product revenue of $52.4 million—a 16% increase fueled by IFC sales hitting $5.6 million, nearly triple the prior year. The company narrowed its net loss to $5.7 million while posting positive non-GAAP adjusted EBITDA of $0.9 million, signaling improving profitability amid R&D investments. Cash reserves stood at $78.0 million. Cerus raised full-year product revenue guidance to $200–$203 million, yet regulatory hurdles for RBC approval persist.
8-K
Board chair retires abruptly
Cerus Corporation's board chair Daniel N. Swisher, Jr., retired effective June 16, 2025, with no disagreements on company matters. The board swiftly appointed CEO William M. Greenman as new chair and Frank Witney, Ph.D., as lead independent director on June 20. Leadership transitions like this ensure continuity. No operational disruptions disclosed.
8-K
Cerus annual meeting approvals
Cerus Corporation's stockholders, at the June 3, 2025 annual meeting, elected Jami Dover Nachtsheim and Hua Shan, MD, Ph.D. to the board through 2028, with strong support—107 million and 111 million votes for, respectively. They approved the 2024 Equity Incentive Plan's amendment by 74 million to 39 million, enhancing stock-based compensation flexibility. Ratification of Ernst & Young as auditors passed overwhelmingly. This bolsters governance continuity.
8-K
Q1 revenue up 13%
Cerus Corporation reported first-quarter 2025 product revenue of $43.2 million, up 13% from $38.4 million a year ago, driven by 22% North American growth despite a 4% EMEA dip from currency headwinds. The company secured CE Mark for its next-gen INT200 LED device ahead of schedule and submitted an updated CE Mark for the INTERCEPT red blood cell system. Cash stood at $80.9 million, with minimal $0.8 million operating burn. It reiterated full-year product revenue guidance of $194–$200 million. Positive adjusted EBITDA signals improving margins, yet regulatory hurdles loom.
AEMD
Aethlon Medical, Inc.
5.75+0.32
CBLL
CeriBell, Inc.
12.03-0.80
CCEL
Cryo-Cell International, Inc.
4.40-0.11
CNMD
CONMED Corporation
46.71-0.61
CRMD
CorMedix Inc.
11.31+0.17
CSDX
CS Diagnostics Corp.
0.36+0.02
CTKB
Cytek Biosciences, Inc.
4.01-0.19
CTSO
Cytosorbents Corporation
0.78-0.05
HAE
Haemonetics Corporation
49.44-0.92
VERO
Venus Concept Inc.
2.18+0.05